Review
Copyright ©2010 Baishideng. All rights reserved.
World J Gastrointest Oncol. May 15, 2010; 2(5): 235-241
Published online May 15, 2010. doi: 10.4251/wjgo.v2.i5.235
Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer
Ioannis A Voutsadakis
Ioannis A Voutsadakis, Department of Medical Oncology, University Hospital of Larissa, Larissa 41110, Greece
Author contributions: Voutsadakis IA contributed solely to this article.
Correspondence to: Ioannis A Voutsadakis, MD, PhD, Department of Medical Oncology, University Hospital of Larissa, Larissa 41110, Greece. ivoutsadakis@yahoo.com
Telephone: +30-241-3502028 Fax: +30-241-3502027
Received: October 19, 2009
Revised: November 30, 2009
Accepted: December 7, 2009
Published online: May 15, 2010
Abstract

Peroxisome proliferator activated receptor-γ (PPARγ), a transcription factor of the nuclear receptor superfamily plays a significant role in colorectal cancer pathogenesis. In most experimental systems PPARγ activation has tumor suppressing effects in the colon. PPARγ is regulated at multiple levels by the ubiquitin-proteasome system (UPS). At a first level, UPS regulates PPARγ transcription. This regulation involves both PPARγ transcription specific factors and the general transcription machinery. At a second level UPS regulates PPARγ and its co-factors themselves, as PPARγ and many co-factors are proteasome substrates. At a third level of regulation, transduction pathways working in parallel but also having interrelations with PPARγ are regulated by the UPS, creating a network of regulation in the colorectal carcinogenesis-related pathways that are under UPS control. Activation of PPARγ transcription by direct pharmacologic activators and by stabilization of its molecule by proteasome inhibitors could be strategies to be exploited in colorectal cancer treatment.

Keywords: Peroxisome proliferator activated receptor-γ, Ubiquitin, Proteasome, Colorectal cancer, Carcinogenesis